Which patients benefit most from tirzepatide GLP-1 for obesity and obstructive sleep apnea?
Wednesday, May 20 – Tirzepatide GLP-1 medication is known to improve sleep apnea for people with both obstructive sleep apnea (OSA) and obesity, but not all patients benefit equally. Now, new research presented at the 2026 ATS International Conference narrows down which patients are likely to have the best treatment outcomes.
Semaglutide for Weight Loss Without Diabetes: What the Approval Covers, What Programs Skip, and What Results Actually Look Like
Tuesday, May 19 – Semaglutide for Weight Loss Without Diabetes: What the Approval Covers, What Programs Skip, and What Results Actually Look Like
Lilly’s Foundayo and Lower-Dose Zepbound Helped People Maintain Weight Loss After Switching from Higher Doses of Injectable Incretin Therapy in Two Late-Phase Trials
Tuesday, May 19 – INDIANAPOLIS, May 12, 2026 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced detailed results from two late-phase trials showing that people with obesity maintained their weight loss long term with either Foundayo or lower-dose…
Wegovy Delivered Substantial Weight Loss in Women Across All Menopause Stages, Plus Heart and Migraine Protection, Shown in New Novo Nordisk Data at the European Congress on Obesity
Tuesday, May 19 – Bagsværd, Denmark, 12 May 2026 – Novo Nordisk today announced data demonstrating that Wegovy® (semaglutide 2.4 mg and 7.2 mg) delivers substantial and consistent weight-loss results for women with obesity across reproductive life…
Wegovy Pill Delivered 21.6% Weight Loss in Early Responders and Doubled Mobility Improvement, According to New Novo Nordisk Data at ECO2026
Tuesday, May 19 – Bagsværd, Denmark, 13 May 2026 – Novo Nordisk today presented new sub-analyses from the phase 3 OASIS 4 clinical trial at the European Congress on Obesity 2026 (ECO2026) in Istanbul, Türkiye, showing how well Wegovy® pill (oral…
STAT+: Maryland state affordability board places a price cap on Ozempic
Tuesday, May 19 – Nine states have been pursuing the idea of prescription drug affordability boards. Maryland’s board just set limits on the price of Ozempic.
Higher Dose Wegovy Demonstrates Nearly 28% Weight Loss in Early Responders According to New Analyses Presented at the European Congress on Obesity
Tuesday, May 19 – Bagsværd, Denmark, 12 May 2026 – Novo Nordisk is presenting a new sub-analysis from the large clinical trial STEP UP at the European Congress on Obesity (ECO) on 12-15 May in Istanbul, Türkiye, showing that the higher dose of the…
At ‘most favored nation’ prices, can Medicare break even on GLP-1 drugs?
Tuesday, May 19 – In November 2025, the White House announced pricing deals with multiple pharmaceutical manufacturers to lower domestic prices for glucagon-like peptide-1 receptor agonist drugs (GLP-1RAs) including Ozempic, Wegovy, Mounjaro, and Zepbound. Those deals are part of a new “most favored nation” (MFN) policy that ties the cost of GLP-1RAs in the U.S. to the prices paid in other wealthy countries.
GLP-1 Drugs like Ozempic, Wegovy May Help Lower Blood Pressure
Tuesday, May 19 – Research shows that GLP-1s may help lower blood pressure levels. Image Credit: Tatiana Maksimova/Getty Images
A recent study found that GLP-1 drugs like Ozempic and Wegovy may significantly reduce blood pressure.
The positive results were observed alongside weight loss and independently of it.
People Who Stopped Taking Ozempic Are Sharing What Actually Happened — And The Answers Are Surprisingly Honest
Monday, May 18, – “That Costco hot dog hit the spot.”View Entire Post ›